Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H27N5O4 |
| Molecular Weight | 437.4916 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN([C@H]4CCCC[C@@H]34)C(=O)C5=CC=CO5
InChI
InChIKey=XBRXTUGRUXGBPX-DLBZAZTESA-N
InChI=1S/C23H27N5O4/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1
| Molecular Formula | C23H27N5O4 |
| Molecular Weight | 437.4916 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23767297Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23767297
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431
CYCLAZOSIN HYDROCHLORIDE is a quinazoline derivative pharmacologically characterized as putative a1B-adrenoceptor antagonist.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL223 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
3.24 nM [Ki] | ||
Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
12.3 nM [Ki] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
0.135 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis and alpha(1)-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin. | 2007-03-15 |
|
| Synthesis and biological profile of the enantiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin- 1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B- adrenoceptor antagonist. | 1996-11-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18037913
Male C-57 WT mice (22–35 g) were injected s.c. with the putative a1B-adrenoceptor antagonist cyclazosin (1.0mg/kg). Cyclazosin was administered 30 min prior to the injection of vehicle (1 ml/kg) or MDMA (20mg/kg). The putative a1B-adrenoceptor antagonist cyclazosin (1mg/kg) in vehicle experiments did not significantly alter the body temperature when compared to vehicle group. The pretreatment of mice with cyclazosin significantly altered the effect of MDMA on core body temperature
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23767297
Sections of the abdominal aorta, obtained from adult female New Zealand rabbits, were treated with agonists and antagonists of adrenergic receptors. Administration of cyclazosin at a dose of 0.002 μM caused a decrease in the muscle tonus of -0.49 ± 0.10 mN. After blockade of the α1B-adrenergic receptor by 0.02 mkM cyclazosin, the administration of 0.05 μM phenylephrine resulted in an increase of the aortic muscle tonus of 1.49 ± 0.14 mN.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:27:50 GMT 2025
by
admin
on
Mon Mar 31 22:27:50 GMT 2025
|
| Record UNII |
2FH26454WF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
132266
Created by
admin on Mon Mar 31 22:27:50 GMT 2025 , Edited by admin on Mon Mar 31 22:27:50 GMT 2025
|
PRIMARY | |||
|
63937
Created by
admin on Mon Mar 31 22:27:50 GMT 2025 , Edited by admin on Mon Mar 31 22:27:50 GMT 2025
|
PRIMARY | |||
|
DTXSID701112809
Created by
admin on Mon Mar 31 22:27:50 GMT 2025 , Edited by admin on Mon Mar 31 22:27:50 GMT 2025
|
PRIMARY | |||
|
2FH26454WF
Created by
admin on Mon Mar 31 22:27:50 GMT 2025 , Edited by admin on Mon Mar 31 22:27:50 GMT 2025
|
PRIMARY | |||
|
210542-51-1
Created by
admin on Mon Mar 31 22:27:50 GMT 2025 , Edited by admin on Mon Mar 31 22:27:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|